Forma Therapeutics and Celgene announced an innovative R&D partnership in 2014 to pursue ground-breaking medicines in oncology and other therapeutic areas.
Biopharmaceutical firm Gilead Sciences has agreed to acquire US-based Kite Pharma for around $11.9bn.
Celgene has revised the terms of its immuno-oncology collaboration with Sutro Biopharma, which was established in 2014.
Dermira has signed a licensing agreement with Roche to secure exclusive rights to lebrikizumab, a monoclonal antibody targeting interleukin 13 (IL-13), for atopic dermatitis and all other indications.
Emergent BioSolutions has agreed to acquire GlaxoSmithKline’s (GSK) anthrax monoclonal antibody, raxibacumab, for around $96m.
The Association of the British Pharmaceutical Industry (ABPI) has applied for judicial review over new procedures that restrict access to cost-effective medicines.
Pfizer has broke ground on a research and development (R&D) and process development facility at 875 W. Chesterfield Parkway, Chesterfield in the US state of Missouri.
Eli Lilly and Company has completed the $90m expansion of its biotechnology center in San Diego, California, US.
Bristol-Myers Squibb has agreed to divest its small molecule active pharmaceutical ingredient manufacturing facility in Swords, Ireland, to South Korea based SK Biotek, a subsidiary of SK Holdings.
Perrigo said its current CEO John Hendrickson is retiring and it has started a search for a replacement.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.